All In Biotech

NDA 215206 · Abbvie

Qulipta

Atogepant · Oral · Calcitonin Gene-related Peptide Receptor Antagonist

NovelPriority review

CDER novel approval, Sep 28, 2021: To prevent episodic migraines

Last checked: Nov 20, 2026Latest source record: Sep 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Sep 28, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

23

17 Phase 3, 7 recruiting

FAERS reports

6,969

2,589 serious, 83 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 30, 2025.

QULIPTA is indicated for the preventive treatment of migraine in adults. QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )

Mechanism: Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 17, 2023 Supplement 4 · Efficacy Label
  • Sep 28, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
3 products under this application
  • QULIPTA · ATOGEPANT 30MG · TABLET, ORAL · Prescription
  • QULIPTA · ATOGEPANT 60MG · TABLET, ORAL · Prescription
  • QULIPTA · ATOGEPANT 10MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Atogepant" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • migraine1,224
  • drug ineffective829
  • headache672
  • nausea639
  • constipation474
  • fatigue446
  • dizziness276
  • therapy interrupted201
  • pain189
  • vomiting188
  • off label use184
  • decreased appetite182

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20171
20193
20208
202128
20221,687
20231,716
2024999
20251,371
20261,155

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qulipta (Atogepant)

2024 spending

$260M

Beneficiaries

45,046

209,816 claims

Per beneficiary

$5,779

$35.98 per unit

View as table
YearSpending
2020$0
2021$1,338,319
2022$51,325,273
2023$137,880,798
2024$260,307,144

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.